BIOMARKAPD General Assembly, April 2015
•Descargar como PPT, PDF•
1 recomendación•12,589 vistas
Derick Mitchell, JPND Communications Manager delivered a JPND update at the BIOMARKAPD General Assembly (JPND-supported project), in Gothenburg, Sweden, on April 24, 2015 For more information on BIOMARKAPD, go to www.biomarkapd.org
Recomendados
Recomendados
Más contenido relacionado
La actualidad más candente
La actualidad más candente (20)
Similar a BIOMARKAPD General Assembly, April 2015
Similar a BIOMARKAPD General Assembly, April 2015 (20)
Más de jpndresearch
Más de jpndresearch (10)
Último
Último (20)
BIOMARKAPD General Assembly, April 2015
- 1. Joint Programming in Neurodegenerative Disease Research (JPND) Coordinating approaches to research across Europe Derick Mitchell BIOMARKAPD General Assembly 24/4/2015
- 2. Overcoming European barriers • Fragmented Research • Non-concerted National Funding • Duplication • Shared research exists via EC (< 5% of total EU budget)
- 3. JPND brings together • Researchers (Basic, Clinical, Healthcare/Social) • National Funding Bodies • National Research Strategies and Investments
- 4. We cannot tackle neurodegenerative diseases by acting as single countries Albania Austria Belgium Canada Croatia Czech Republic Denmark Finland France Germany Greece Hungary Ireland Israel Italy Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden Switzerland Turkey United Kingdom JPND is the largest global ND research initiative led by EU countries, with 28 participating EU member states Associated countries Third countries Increasing coordination of national research programmes to improve impact and effectiveness A European Research Area and beyond Australia TBC
- 5. Defragmentation – what JPND is all about… STRATEGIC RESEARCH AGENDA ALIGNMENT OF EU COUNTRIES ON COMMON RESEARCH GOALS
- 6. JPND Actions to date • Common European Strategy (2012) • Phase I Implementation (‘12-’14) • Joint Transnational Calls (6) • Alignment Actions (9) • National Plans and Strategies • Communication + Dissemination
- 7. SRA Implementation (2012-2014) Annual Calls for Proposals Year Total fund Research Area No. of Projects 2011 (pilot) €16M Optimization of biomarkers + harmonization of their use 4 2012 €18M Risk and Protective Factors 5 2012 €11M Evaluation of Healthcare 6 2013 €12M Cross-Disease Analysis 10 2013 €11M Preventive Strategies 5 2014 €0.5M Working Groups Cohort Studies 10 2015 €30M Longitudinal Cohort Approaches; Advanced Experimental Models; Risk and Protective Factors. Closed March 10th AG
- 8. JPND Annual Call Statistics Year Call area of interest No. of proposals submitted Budget requested (million €) No. of proposals recommended for funding No. of proposals supported Budget supported (million €) Success rate (%) 2011 Harmonization of Biomarkers 14 €31 5 4 €14 29% 2012 Risk and Protective Factors 52 €97 18 5 €17 10% 2012 Healthcare Evaluation 22 €29 9 6 €9 27% 2013 Cross-Disease Analysis 90* €112 23 10 €12.5 11% 2013 Pilot Preventive Strategies 35* €36 5 5 €7 14% Total 213 €157m 60 30 €59.5m 18% * pre-proposals
- 9. SRA Implementation JPND Alignment Actions
- 11. “Rapid Action” Call for working groups
- 12. Global action against dementia G7/WHO
- 13. Fostering greater collaboration Join our Online Partnering Tool IT 18% DE 16% ES 9% UK 9% FR 5% PT 5% SE 4% CA 4% NO 3% BE 3% PL 3% IE 2% NL 2% LU 2% FI 2% DK 2% CH 2% AU 2% OTHERS 5% 953 Profiles 38 Countries
- 14. Dissemination and Communication Guidelines Updated October 2014
- 17. Keep up to date • Visit the JPND website: • http://www.jpnd.eu • Sign up to the JPND News Feeds • E-mail us: secretariat@jpnd.eu @JPNDEurope
Notas del editor
- Close to 85% of public research funds in the EU are spent independently by Member States
- To address these diseases in their entirety
- The challenge of addressing neurodegenerative diseases such as Alzheimer’s and Parkinson’s is a truly global one. Most neurodegenerative diseases (ND) are incurable and are strongly linked with age.
- JPND will…… Enhance research capacity Reduce duplication of research Increase research coordination Improve outcomes and care
- (CoEN) 2011 Call for € 6M 2012-13 Call for € 8M – Pathfinder “high risk, high return” projects 28 countries working together to tackle neurodegenerative diseases, in particular Alzheimer’s €100 million made available since 2011 New partnership with European Commission €30 million call on: Longitudinal cohorts Animal and Cell Models Risk and Protective Factors
- Over €100 million will be made available
- Reports and recommendations from Action Groups feed into the overall Phase 1 Implementation plan, with the JPND Management Board making the decision on which initiatives to start and when to start them. Mapping excercisecomprehensive landscape Workshop with experts Identification of gaps and unmet needs Recommendations to MB MB decides which actions should be implemented, for ex. JTC for Working Groups (AG cohorts) PPI in JTC 2015 You can keep up-to-date on outputs from Action Groups, and funded projects on the “JPND Progress” pages on the JPND website
- Coordination and development of best practice Ten JPND working groups to address methodological challenges for longitudinal cohort studies such as: Cognition / Functional assessment Biomarkers Biobanking Imaging Health and social outcomes Presymptomatic ND
- JPND-supported projects and activities are encouraged to take part in various activities to bring JPND-supported research to the attention of as many relevant people as possible, including dissemination, communication and exploitation. ‘Dissemination and Communication’ are more than just an additional reporting burden. Communicating about JPND research which involves several JPND member countries aims to demonstrate the ways in which JPND research is contributing to future economic growth and jobs on a national and European level, and should also account for public spending by providing tangible proof that collaborative research adds value by: showing how international collaboration has achieved more than would have otherwise been possible, notably in achieving scientific excellence, contributing to competitiveness and tackling the challenge of neurodegenerative diseases. showing how the research outcomes are relevant to the public’s everyday lives, by (for example) creating jobs, making patient and carers’ lives more comfortable, alleviating economic + social burden. making better use of the results, by making sure they are taken up by decision-makers to influence policy-making and by industry and the scientific community to ensure follow-up. Strategically-planned communication with these objectives in mind is significantly different to ad hoc efforts for the sake of meeting contractual requirements.